Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Print1
- Journal1
- Article Type
- Clinical Trial1
- Clinical Study1
- Comparative Study1
- Controlled Clinical Trial1
- Result From
- Lane Catalog1
- PubMed1
- SearchWorks (biomedical subset) 1
-
Year
- Journal Title
- Lancet1
Search Results
Sort by
- Journal
- ArticlePowles RL, Russell JA, Selby PJ, Prentice HG, Jones DR, McElwain TJ, Alexander P.Lancet. 1977 Nov 26;2(8048):1107-10.Thirty patients with acute myelogenous leukaemia (A.M.L.) in full haematological remission were allocated alternately to two groups of fifteen patients each. All patients received immunotherapy, given weekly as intradermal and subcutaneous injections of killed allogeneic A.M.L. cells, plus Glaxo B.C.G. given by Heaf gun at a separate site. One group also received a mixture of A.M.L. cells and B.C.G. on 4 occasions early in remission. Four patients in this group have remained in remission for 92 to 134 weeks, whereas all patients in the other group had relapsed by 68 weeks. The findings suggest that cells mixed with B.C.G. may be effective in prolonging remission.